
Financial statements of
The Kidney Foundation of Canada

December 31, 2020

Independent Auditor’s Report	1-2
Statement of operations.....	3
Statement of changes in fund balances	4
Statement of financial position	5
Statement of cash flows	6
Notes to the financial statements	7-15



Deloitte LLP
La Tour Deloitte
1190 Avenue des
Canadiens-de-Montréal
Suite 500
Montréal QC H3B 0M7
Canada

Tel: 514-393-7115
Fax: 514-390-4116
www.deloitte.ca

Independent Auditor's Report

To the Directors of
The Kidney Foundation of Canada

Opinion

We have audited the financial statements of The Kidney Foundation of Canada (the "Kidney Foundation"), which comprise the statement of financial position as at December 31, 2020, and the statements of operations, changes in fund balances and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies (collectively referred to as the "financial statements").

In our opinion, except for the possible effects of the matter described in the *Basis for Qualified Opinion* section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Kidney Foundation as at December 31, 2020, and the results of its operations and cash flows for the year then ended, in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Qualified Opinion

Until December 31, 2019, in common with many not-for-profit organizations, for the Kidney Foundation's revenue from fundraising activities, the completeness of such revenue was not susceptible to satisfactory audit verification. Accordingly, verification of these revenues in our 2019 audit was limited to the amounts recorded in the records of the Kidney Foundation. Therefore, we were not able to determine whether any adjustments might be necessary to public support, excess of revenue over expenditures, and cash flows from operations for the year ended December 31, 2019, current assets as at December 31, 2019, and fund balances as at January 1 and December 31, 2019. Our audit opinion on the financial statements for the year ended December 31, 2019, was modified because of the possible effects of this limitation in scope. As a result, our opinion on the current year's financial statements is modified because of the possible effects of this matter on the comparability of the current period's figures and the comparative information.

We conducted our audit in accordance with Canadian generally accepted auditing standards ("Canadian GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Kidney Foundation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Kidney Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Kidney Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Kidney Foundation's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian GAAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian GAAS, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Kidney Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Kidney Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Kidney Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Deloitte LLP

June 5, 2021

¹ CPA auditor, CA, public accountancy permit No. A125888

The Kidney Foundation of Canada
Statement of operations
Year ended December 31, 2020

	Notes	2020	2019
		\$	\$
Revenue			
Public support		20,517,759	23,385,900
Bequests and In Memoriam		2,801,153	2,321,489
Transfer of surplus from The Canadian Kidney Trustee Corporation	13	187,952	882,985
Investment income allocated to operations	5 and 6	672,938	1,008,325
		24,179,802	27,598,699
Fundraising expenditures		8,336,555	10,913,447
Net revenue		15,843,247	16,685,252
Expenditures			
Programs			
Research		2,554,618	4,190,143
Patient services		3,151,548	3,438,233
Organ donation awareness		672,270	1,057,547
Public education services and communications		3,041,511	3,377,675
Kidney Foundation development		472,471	957,683
		9,892,418	13,021,281
Management and administration		2,872,881	3,623,350
		12,765,299	16,644,631
Excess of revenue over expenditures before the following		3,077,948	40,621
Investment (loss) income not allocated to operations	5 and 6	(587,435)	754,291
Excess of revenue over expenditures		2,490,513	794,912

The accompanying notes are an integral part of the financial statements.

The Kidney Foundation of Canada
Statement of changes in fund balances
Year ended December 31, 2020

	Unrestricted	Invested in capital assets	Internally restricted (Note 9)	Externally restricted for endowments (Note 8)	Total
	\$	\$	\$	\$	\$
Fund balances, December 31, 2018	4,465,692	484,333	8,312,060	4,732,509	17,994,594
Excess (deficiency) of revenue over expenditures excluding investment income not allocated to operations	398,202	(75,917)	(281,664)	—	40,621
Investment income not allocated to operations	—	—	754,291	—	754,291
Endowment contributions	—	—	—	30,902	30,902
Reinvested investment income	—	—	—	11,347	11,347
Interfund transfers	(805,831)	105,721	700,110	—	—
Fund balances, December 31, 2019	4,058,063	514,137	9,484,797	4,774,758	18,831,755
Excess (deficiency) of revenue over expenditures excluding investment income not allocated to operations	3,917,701	(88,107)	(751,646)	—	3,077,948
Investment loss not allocated to operations	—	—	(587,435)	—	(587,435)
Endowment contributions	—	—	—	17,473	17,473
Reinvested investment income	—	—	—	11,801	11,801
Interfund transfers	(4,603,891)	70,217	4,533,674	—	—
Fund balances, December 31, 2020	3,371,873	496,247	12,679,390	4,804,032	21,351,542

The accompanying notes are an integral part of the financial statements.

The Kidney Foundation of Canada
Statement of financial position
As at December 31, 2020

	Notes	2020 \$	2019 \$
Assets			
Current assets			
Cash		6,609,011	2,111,599
Due from The Canadian Kidney Trustee Corporation	13	467,210	907,311
Interest and sundry receivable		2,268,700	1,930,907
Prepaid expenses		454,829	485,095
		9,799,750	5,434,912
Capital assets			
Investments	3	963,064	998,571
	4	18,050,038	19,843,427
		28,812,852	26,276,910
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities	10	1,645,020	1,503,405
Deferred contributions	7	4,881,944	5,116,509
Deferred contributions – KRESCENT program	7	467,529	340,807
Deferred contributions – capital assets	7	466,817	484,434
		7,461,310	7,445,155
Commitments and contractual obligations			
	11		
Fund balances			
Unrestricted		3,371,873	4,058,063
Contributed land		335,000	335,000
Invested in capital assets		161,247	179,137
Internally restricted	9	12,679,390	9,484,797
Externally restricted for endowments	8	4,804,032	4,774,758
		21,351,542	18,831,755
		28,812,852	26,276,910

The accompanying notes are an integral part of the financial statements.

Approved by the Board



_____, Director



_____, Director

The Kidney Foundation of Canada

Statement of cash flows

Year ended December 31, 2020

	2020	2019
	\$	\$
Operating activities		
Excess of revenue over expenditures	2,490,513	794,912
Adjustments for:		
Amortization of capital assets	130,131	116,672
Amortization of deferred contributions – capital assets	(42,024)	(40,755)
Gain on sale of investments	(5,914)	(27,052)
Unrealized change in fair value of investments	905,663	(1,662,332)
Deferred contributions recognized as revenue	(1,482,154)	(1,499,523)
	1,996,215	(2,318,078)
Changes in non-cash operating working capital items		
Due from The Canadian Kidney Trustee Corporation	440,101	(137,232)
Interest and sundry receivable	(337,793)	(407,252)
Prepaid expenses	30,266	223,972
Accounts payable and accrued liabilities	141,615	(100,245)
	274,189	(420,757)
Increase in deferred contributions	1,746,394	1,515,576
(Decrease) increase in deferred contributions – restricted investment income	(347,676)	631,550
	1,398,718	2,147,126
	3,669,122	(591,709)
Investing activities		
Acquisition of investments	(1,272,451)	(2,419,170)
Proceeds on sale of investments	2,166,091	987,108
Acquisition of capital assets	(94,624)	(107,721)
	799,016	(1,539,783)
Financing activities		
Endowment contributions	17,473	30,902
Reinvested investment income	11,801	11,347
	29,274	42,249
Net increase (decrease) in cash	4,497,412	(2,089,243)
Cash, beginning of year	2,111,599	4,200,842
Cash, end of year	6,609,011	2,111,599

The accompanying notes are an integral part of the financial statements.

1. Mission of The Kidney Foundation of Canada

The Kidney Foundation of Canada is committed to achieving excellent kidney health, optimal quality of life, and a cure for kidney disease. The Kidney Foundation of Canada (the "Kidney Foundation") is the national volunteer organization committed to eliminating the burden of kidney disease through:

- funding and stimulating innovative research for better treatments and a cure;
- providing education and support to prevent kidney disease in those at risk and empower those with kidney disease to optimize their health status;
- advocating for improved access to high-quality health care; and
- increasing public awareness and commitment to advancing kidney health and organ donation.

The Kidney Foundation relies on its extensive network of qualified volunteers working in partnership with staff to deliver its programs and services throughout Canada. The Kidney Foundation is a registered charity under the *Income Tax Act* and is incorporated under the laws of Canada.

2. Accounting policies

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations ("ASNPO") and include the following significant accounting policies:

Financial instruments

Financial assets and financial liabilities are initially recognized at fair value when the Kidney Foundation becomes a party to the contractual provisions of the financial instrument. Subsequently, all financial instruments are measured at amortized cost, except for investments, which are measured at fair value at the closing date. The fair value of investments is based on closing prices. Fair value fluctuations, including interest earned, interest accrued, gains and losses realized on sale, and unrealized gains and losses, are included in investment income.

Transaction costs related to investments are expensed as incurred. Transaction costs related to the other financial instruments are added to the carrying value of the asset or netted against the carrying value of the liability and are then recognized over the expected life of the instrument using the straight-line method. Any premium or discount related to an instrument measured at amortized cost is amortized over the expected life of the item using the straight-line method and recognized in the statement of operations as interest income or expense.

With respect to financial assets measured at cost or amortized cost, the Kidney Foundation recognizes in the statement of operations an impairment loss, if any, when it determines that a significant adverse change has occurred during the period in the expected timing or amount of future cash flows. When the extent of impairment of a previously written-down asset decreases and the decrease can be related to an event occurring after the impairment was recognized, the previously recognized impairment loss shall be reversed in the statement of operations in the period the reversal occurs.

2. Accounting policies (continued)

Revenue recognition

The Kidney Foundation uses the deferral method of accounting for contributions. Contributions are recognized during the year in which they are received. Pledged contributions not received are not recorded. Unrestricted contributions are recognized as revenue when received. Restricted contributions are recorded as deferred contributions and recognized as revenue when the related expense is incurred or the related capital assets are amortized. Contributions for endowments are recognized as direct increases in the endowment fund balance.

Unrestricted investment income is recognized as revenue when earned. Restricted investment income is recorded as a deferred contribution and is recognized when the related expense is incurred. Investment income required to be added to the endowment is recognized as a direct increase in the endowment fund balance.

Up to 4% of the fair value of investments is reported as investment income allocated to operations. With the approval of the National Board of Directors, additional investment income may be allocated to operations for specific purposes. The excess or shortfall, if any, is reported as investment income not allocated to operations and is transferred to the investment income reserve.

Revenues from fundraising activities are presented on a gross basis when the Kidney Foundation is considered to be the principal involved in the activity. Certain revenues generated from highly regulated government programs that result in net proceeds to the Kidney Foundation are recorded at the amount of net proceeds generated.

Donated services

The Kidney Foundation derives significant benefit from time and services donated by volunteers. These valuable contributions are not recorded in the financial statements.

Capital assets

Capital assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives. Furniture and fixtures and other capital assets are amortized over five years. Computer equipment is amortized over three years. The building was donated and recorded at its appraised fair value and is being amortized over 25 years.

Allocations

The Kidney Foundation classifies its activities between Kidney Foundation development, management, and administration activities, and its four program-related activities: research, patient services, organ donation awareness, and public education services and communications. The cost of each activity includes the direct costs associated with those activities, including personnel costs and other direct expenses. In addition, the Kidney Foundation incurs a certain number of common operating expenses in connection with these activities. The Kidney Foundation performs a review of its cost allocations on an annual basis to ensure that they remain consistent with changes to its operating activities. Changes to such allocations are applied in the year of the revision.

Where shared or indirect costs relate to more than one activity, the Kidney Foundation allocates these costs according to the efforts of each activity. These costs include expenditures related to administrative staff, rental costs, and other operating costs that cannot be charged directly to a specific activity. Eligible expenditures are allocated based on either physical space used or staff time allocated to an activity.

The Kidney Foundation allocates a portion of its fundraising costs to public education for one of its fundraising activities on the basis that some of the communication messages used in this activity are primarily educational in nature and promote public engagement. The costs are allocated based on management's best estimate of the portion of the direct costs of the educational materials that apply to a non-fundraising activity.

2. Accounting policies (continued)

Government assistance

Amounts received or receivable resulting from government assistance programs are recorded as reductions of the cost of assets or expenses to which they relate when the Kidney Foundation becomes eligible to accrue them, provided there is reasonable assurance the benefits will be realized. Government assistance, including the Canada Emergency Wage Subsidy (CEWS), was recorded as a reduction of fundraising and operating expenses in the statement of operations. The CEWS is subject to review by the Canadian tax authorities.

Use of estimates

The preparation of financial statements in conformity with Canadian ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.

3. Capital assets

	2020			2019
	Cost	Accumulated amortization	Net book value	Net book value
	\$	\$	\$	\$
Building	930,000	479,100	450,900	488,100
Land	335,000	—	335,000	335,000
Computer equipment	969,050	874,692	94,358	88,521
Furniture and fixtures	365,818	286,973	78,845	80,921
Others	39,713	35,752	3,961	6,029
	2,639,581	1,676,517	963,064	998,571

4. Investments

	2020			2019		
	Fair value	Cost	Unrealized gain	Fair value	Cost	Unrealized gain (loss)
	\$	\$	\$	\$	\$	\$
Money market funds	2,039,980	1,998,474	41,506	3,630,603	3,661,938	(31,335)
Bond funds	3,220,919	3,094,505	126,414	3,306,278	3,277,548	28,730
Canadian equity funds	4,627,358	4,574,083	53,275	4,627,862	4,377,022	250,840
International equity funds	8,161,781	8,053,391	108,390	8,278,684	7,291,671	987,013
	18,050,038	17,720,453	329,585	19,843,427	18,608,179	1,235,248

The values of investments are based on their fair values at the end of the reporting period.

5. Investment income

Investment income is composed of:

	2020	2019
	\$	\$
Gain on sale of investments	5,914	27,052
Fund distributions related to dividends and interest	649,377	716,129
Unrealized change in fair value of investments	(905,663)	1,662,332
	(250,372)	2,405,513

The presentation of investment income in the financial statements is as follows:

	2020	2019
	\$	\$
Statement of operations		
Investment income allocated to operations	672,938	1,008,325
Investment (loss) income not allocated to operations (Note 6)	(587,435)	754,291
Direct increase in deferred contributions		
Investment (loss) income from externally restricted endowments (Note 7a)	(363,190)	600,521
Investment income allocated to deferred contributions	15,514	31,029
Statement of changes in fund balances		
Investment income reinvested in endowment capital	11,801	11,347
	(250,372)	2,405,513

6. Investment income reserve

In accordance with the Kidney Foundation's income appropriation policy, investment income allocated to operations is determined at the beginning of the year as a percentage of the fair value of investments, with a maximum allocation of 4%. With the approval of the National Board of Directors, additional investment income may be allocated to operations for specific purposes. Excess income over the amount allocated is recorded as investment income not allocated to operations. In the event that the actual income is less than the amount allocated, the shortfall is taken from the investment income reserve and is recorded as a negative in the investment income not allocated to operations. The objectives of this policy are to provide a more stable amount of investment income to operations annually and to help maintain the capital, including in years when the market does not perform well.

	2020	2019
	\$	\$
Balance, beginning of year	2,176,386	1,422,095
Investment (loss) income not allocated to operations	(587,435)	754,291
Balance, end of year	1,588,951	2,176,386

In 2017, the National Board of Directors established an Innovation Fund which is funded from investment income to be allocated to operations.

The investment income reserve balance at year-end includes a commitment of \$261,508 (\$61,508 in 2019) for the Innovation Fund. The investment income reserve is a component of internally restricted funds (Note 9).

7. Deferred contributions

a) *Deferred contributions*

Deferred contributions consist of contributions which the donor has restricted to a specific purpose, plus restricted investment income on externally restricted endowments. These amounts are only recognized in income when expenditures meeting the restriction are incurred. The Kidney Foundation complies with these external restrictions.

	Beginning	Additions	Disbursements	Balance, end of year
	\$	\$	\$	\$
Investment income (loss) on externally restricted endowments (Note 5)	1,641,983	(363,190)	—	1,278,793
Patient services	801,985	862,145	535,470	1,128,660
Research	777,453	193,660	287,442	683,671
Organ donation awareness	755,002	42	230,388	524,656
Others	731,425	122,820	270,122	584,123
Public education services and communications	408,661	409,209	135,829	682,041
	5,116,509	1,224,686	1,459,251	4,881,944

b) *Deferred contributions – KRESCENT program*

The Kidney Foundation is responsible for the Kidney Research Scientist Core Education and National Training Program (KRESCENT) secretariat that manages the overall program and raises and administers funds for the initiative. The funds raised by the Kidney Foundation, and dedicated to the program, are subject to the normal accounting policies and practices of the Kidney Foundation's research program.

	2020	2019
	\$	\$
Balance, beginning of year	340,807	430,333
Plus: sponsorships and donations received	149,625	77,739
Less: amount recognized as revenue during the year	(22,903)	(167,265)
Balance, end of year	467,529	340,807

c) *Deferred contributions – capital assets*

This balance includes donated capital assets and capital assets purchased with funds restricted for that purpose.

	2020	2019
	\$	\$
Balance, beginning of year	484,434	523,190
Plus: contributions received	24,407	1,999
Less: amount recognized as revenue during the year	(42,024)	(40,755)
Balance, end of year	466,817	484,434

8. Externally restricted for endowments

Externally restricted for endowments consist of the original endowment contribution amounts.

	2020	2019
	\$	\$
Research	2,387,380	2,380,218
Other designated activities	2,082,743	2,060,911
Undesignated	333,909	333,629
	4,804,032	4,774,758

The fair value adjustment for the externally restricted endowments is reflected in the deferred contributions.

9. Internally restricted fund balance

The internally restricted fund balance consists of resources designated by the National Board of Directors for specific purposes. This fund balance is composed of the following components:

	2020	2019
	\$	\$
Surpluses for use in future years	6,918,256	3,415,309
Three years commitment for research	3,875,105	3,171,024
Investment income reserve (Note 6)	1,588,951	2,176,386
Strategic project	—	425,000
Capacity building for Saskatchewan	190,548	190,548
Future capital expenditures in Southern Alberta	80,000	80,000
Programs in Manitoba	26,530	26,530
	12,679,390	9,484,797

In 2016, the National Board of Directors approved a policy to encourage long-term fiscal responsibility. This policy permits branches and the national office to carry forward a portion of their share of the consolidated surplus for spending in future years.

10. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities include \$3,572 (\$5,182 as at December 31, 2019), of government remittances.

11. Commitments and contractual obligations

The Kidney Foundation has commitments for research (including the KRESCENT program). These commitments less deferred contributions for research amount to \$3,156,355. In addition, the Kidney Foundation signed an agreement for five years in 2017 with Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can SOLVE CKD). The commitment for this project represents \$318,750. The Kidney Foundation signed a letter of intent with Canadian Institutes of Health Research in 2019 for \$1,000,000 over five years. The project will start in 2022 and ends in 2026. The Kidney Foundation has minimum rental obligations under existing long-term operating leases, exclusive of certain operating costs, for which the Kidney Foundation is also responsible totalling \$2,407,891. These amounts are expected to be disbursed in the forthcoming years as follows:

	Research commitments	Contractual obligations
	\$	\$
2021	2,033,535	680,928
2022	1,544,851	484,331
2023	296,719	280,175
2024	200,000	270,701
2025 and thereafter	400,000	691,756

12. Allocations

As described in the accounting policies, management and administration expenditures have been allocated as follows:

	2020	2019
	\$	\$
Patient services	591,466	609,011
Public education services and communications	333,489	327,914
Fundraising expenditures	208,552	224,752
Research	150,959	270,176
Kidney Foundation development	115,512	181,457
Organ donation awareness	108,361	164,085

As described in the accounting policies, certain expenditures incurred coincidentally with fundraising have been allocated to other activities as follows:

	2020	2019
	\$	\$
Public education services and communications	149,339	140,182

13. Related-party transactions

The Kidney Foundation has an economic interest in The Canadian Kidney Trustee Corporation (the "Trust"), since the Trust is the national volunteer organization committed to raise funds in support of the Kidney Foundation by collecting and selling donated items, including clothing and household goods. During the year, the Kidney Foundation carried out transactions with the Trust, which took place during the normal course of business and are measured at the exchange amount. The balance due between these related parties is presented separately in the financial statements.

During the year, the Kidney Foundation charged the Trust management fees of \$73,704 (\$73,704 in 2019) for administrative services rendered.

The summary of financial information of the Trust as at December 31, 2020 and 2019, and for the years then ended, is as follows:

	2020	2019
	\$	\$
Statement of financial position		
Assets	1,100,958	1,251,823
Liabilities	1,100,958	1,251,823
Liabilities include an amount due to the Kidney Foundation of \$467,210 (\$907,311 in 2019)		
Statement of operations		
Total revenue	2,646,436	5,973,681
Total expenditures	2,458,484	5,090,696
Transfer of surplus to the Kidney Foundation	187,952	882,985
Excess of revenue over expenditures	—	—
	2020	2019
	\$	\$
Statement of cash flows		
Operating activities	(540,816)	317,954
Investing activities	(3,834)	(1,794)
Financing activities	—	(202)
(Decrease) increase in cash	(544,650)	315,958

14. Financial instruments

Credit risk

The Kidney Foundation is exposed to credit risk to the extent that its donors and debtors may experience financial difficulty and would be unable to meet their obligations; however, the Kidney Foundation has a large number of diverse donors and debtors, which minimizes concentration of credit risk.

Market risk

The Kidney Foundation's investment portfolio is subject to market risk, which is the risk that the value of a financial instrument will fluctuate as a result of changes in market prices, whether those changes are caused by factors specific to the individual security or its issuer or factors affecting all securities traded in the market. This risk includes exposure to fluctuations in interest rates and in foreign currencies. The Kidney Foundation's investment portfolio is professionally managed following a diversified investment strategy to manage risk. The portfolio is monitored on a periodic basis by the Kidney Foundation's National Finance and Audit Committee and Investment Committee.

Liquidity risk

The Kidney Foundation's objective is to have sufficient liquidity to meet its liabilities when due. The Kidney Foundation monitors its cash balances and cash flows generated from operations to meet its requirements. As at December 31, 2020, the most significant financial liabilities are accounts payable and accrued liabilities.

15. Supplemental information

In 2020, total remuneration paid to employees of the province of Alberta whose principal duties include fundraising was \$167,314 (\$197,313 in 2019).

16. COVID-19

On March 11, 2020, the World Health Organization characterized the outbreak of a strain of the novel coronavirus ("COVID-19") as a pandemic which has resulted in the implementation of a series of public health and emergency measures aimed at containing the spread of the virus. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. While management is monitoring the situation, given the dynamic nature of these circumstances, the expected duration and the related financial impact cannot be reasonably estimated at this time.

In response to COVID-19, the Canadian government has put in place certain assistance programs. During the year, the Kidney Foundation recorded a reduction of its fundraising and operating expenses in an amount of \$2,399,199 in connection with these programs.

17. Comparative figures

Certain comparative figures have been reclassified to conform to the presentation adopted in the current year.